


(R)-(+)-Anatabine

| | |
|--------------------|---|
| Cat. No.: | HY-126047B |
| CAS No.: | 126454-22-6 |
| Molecular Formula: | C ₁₀ H ₁₂ N ₂ |
| Molecular Weight: | 160.22 |
| Target: | NF-κB; Amyloid-β; nAChR |
| Pathway: | NF-κB; Neuronal Signaling; Membrane Transporter/Ion Channel |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

Description

(R)-(+)-Anatabine is a less active R-enantiomer of Anatabine. Anatabine is a potent $\alpha 4\beta 2$ nAChR agonist^[1]. Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment^{[2][3][4]}.

REFERENCES

- [1]. Jothi L, Nallasivam, et al. Synthetic modifications of bifunctional homoallylamines: Synthesis of 2-arylpiperidines, (R)-anatabine and (R)-anabasine. An International Journal for Rapid Communication of Synthetic Organic Chemistry. Volume 49, 2019-Issue 21: 2815-2822.
- [2]. Paris D, et al. Anatabine lowers Alzheimer's Aβ production in vitro and in vivo. Eur J Pharmacol. 2011 Nov 30;670(2-3):384-91.
- [3]. Xing H, et al. A Pharmacological Comparison of Two Isomeric Nicotinic Receptor Agonists: The Marine Toxin Isoanatabine and the Tobacco Alkaloid Anatabine. Mar Drugs. 2020 Feb 11;18(2). pii: E106.
- [4]. eo EJ, et al. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease. Pharmacol Res. 2018 Mar;129:262-273.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA